Granted Patent B2

US 8,802,381 · App. 13/846,172 · Granted Aug 12, 2014

Inventors: John O'Connor (New Rochelle, NY); Steven Birken (Damascus, MD); Galina Kovalevskaya (Bronx, NY)

Assignee: The Trustees of Columbia University in the City of New York

Abstract

Claims (31)

1. A method for monitoring effectiveness of an infertility treatment comprising:

(a) obtaining a first sample from a subject undergoing the infertility treatment;

(b) contacting the first sample with a capture antibody which specifically binds to the early pregnancy associated molecular isoform of Human chorionic gonadotropin (EPMI-hCG), which isoform is recognized by the antibody produced by hybridoma cell line B152 (ATCC Designation No. HB-12467) under conditions permitting formation of a complex between the capture antibody and EPMI-hCG in the first sample;

(c) measuring the amount of complexes formed in step (b), thereby determining the amount of EPMI-hCG in the first sample;

(d) obtaining a second sample from the subject after a period of time;

(e) contacting the second sample with the capture antibody under conditions permitting formation of a complex between the capture antibody and EPMI-hCG in the second sample;

(f) measuring the amount of complexes formed in step (e), thereby determining the amount of EPMI-hCG in the second sample;

(g) comparing the amount of EPMI-hCG determined in step (c) with the amount determined in step (f);

(h) determining that the infertility treatment is effective if the amount determined in step (f) is higher than that determined in step (c); or determining that the infertility treatment is ineffective if the amount determined in step (f) is not higher than that determined in step (c) .

2. The method of claim 1 , wherein the complexes formed in step (b) and in step (e) are detected by a detection antibody.

3. The method of claim 2 , wherein the detection antibody is B207.

4. The method of claim 2 , wherein the detection antibody is labeled with a detectable marker.

5. The method of claim 4 , wherein the detectable marker is a radioactive isotope, enzyme, dye, magnetic bead, or biotin.

6. The method of claim 5 , wherein the radioactive isotope is I 125 .

7. The method of claim 1 , wherein the first sample is a urine sample or a blood sample.

8. The method of claim 1 , wherein the second sample is a urine sample or a blood sample.

9. The method of claim 1 , wherein the period of time in step (d) is not more than 8 weeks.

10. The method of claim 9 , wherein the period of time in step (d) is not more than 6 weeks.

11. The method of claim 10 , wherein the period of time in step (d) is not more than 5 weeks.

12. A method for detecting trophoblastic cancer in a subject comprising:

(a) contacting a sample from the subject with monoclonal antibody B151 under conditions permitting formation of a complex between B151 and nicked Human chorionic gonadotropin (hCG) in the sample;

(b) determining the amount of complexes formed in step (a) thereby determining the amount of nicked hCG in the sample; and

(c) comparing the amount of nicked hCG in the sample determined in step (b) with the amount determined for a healthy control subject,

(d) determining that the subject is afflicted with trophoblastic cancer if the level of nicked hCG in the sample is elevated compared to that determined for the healthy control subject.

13. The method of claim 12 , wherein the complex formed in step (a) is detected by a detection antibody.

14. The method of claim 13 , wherein the detection antibody is B604.

15. The method of claim 13 , wherein the detection antibody is labeled with a detectable marker.

16. The method of claim 15 , wherein the detectable marker is a radioactive isotope, enzyme, dye, magnetic bead, or biotin.

17. The method of claim 16 , wherein the radioactive isotope is I 125 .

18. The method of claim 12 , wherein the sample is a urine sample or a blood sample.

19. The method of claim 12 , wherein the trophoblastic cancer is choriocarcinoma.

Assignments (2)

Continuity (9)